Navigation Links
Immunotherapy reduces allergic patients' sensitivity to peanuts

Of all foods, peanuts are the most frequent cause of life-threatening and fatal allergic reactions. New research at National Jewish Health provides additional support for a strategy to reduce the severity of reactions to peanut repeatedly consuming small amounts of the very food that causes those reactions in the first place, a practice called immunotherapy.

The new research, published in the January 2013 issue of The Journal of Allergy & Clinical Immunology, shows that 70 percent of peanut-allergic patients who consumed daily doses of peanut protein in liquid drops could safely consume 10 times as much peanut protein as they had before the therapy. One patient's serious reaction, however, highlighted the care that must be taken to keep patients safe.

"Immunotherapy continues to show promise for treating food allergies," said lead author David Fleischer, MD, associate professor of pediatrics at National Jewish Health. "But it is not yet ready for widespread use; there is a fine line between safely desensitizing patients and causing serious allergic reactions. We are still working to discover where that line is and how to select patients who would most likely benefit."

Immunotherapy, in the form of allergy shots, has been used for more than a century to reduce patients' allergic reactions, mostly to pollen. Patients are injected with gradually increasing amounts of protein until they reach a "maintenance level," which they continue for two to five years. The current trial delivers immunotherapy through drops containing peanut protein placed under the tongue.

Somehow this small, but repeated exposure changes the way that the immune system 'sees' the proteinfrom mistakenly considering it a dangerous invader to accurately recognizing it as a harmless piece of the environment. Scientists do not understand exactly how this occurs. In recent years, there has been renewed interest in understanding and exploring new methods of immunotherapy for a variety of immune disorders.

In the current trial, researchers reported interim results of a study that enrolled 40 teenage and adult patients with moderate, but not severe, reactions to peanuts. They divided them evenly into groups receiving either peanut protein or a placebo. The participants took the drops daily at home, coming into National Jewish Health and other academic medical centers for increased doses. Patients will continue immunotherapy for approximately three years.

After 44 weeks, 70 percent of the participants receiving peanut immunotherapy increased the average amount of peanut protein they could safely consume from 3.5 milligrams to 496 milligrams. After 68 weeks, responders were desensitized further, safely consuming, on average, 996 milligrams of peanut protein. That level of desensitization could help protect against an accidental ingestion, which averages about 100 milligrams. One peanut contains on average about 250 milligrams of peanut protein.

"We are hopeful that continued immunotherapy will help more patients become less sensitive to peanuts," said Dr. Fleischer.

Even at relatively low doses, participants frequently experienced some symptoms, most commonly itching in the mouth and throat. One patient developed very itchy red skin and more serious symptoms in the mouth after a daily dose at home. The patient required an antihistamine, an epinephrine injection and close observation at one of the research centers.

"This is an experimental treatment, promising, but with potentially serious side effects," said Dr. Fleischer. "Some physicians are treating their peanut-allergic patients with immunotherapy outside of carefully controlled and observed trials. I don't think that approach is safe until we better understand how much protein to deliver, through what method, and to which patients."


Contact: William Allstetter
National Jewish Health

Related medicine news :

1. Sublingual immunotherapy shows promise as treatment for peanut allergy
2. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
3. Antibodies reverse type 1 diabetes in new immunotherapy study
4. Immunotherapy for elderly cancer patients finds new promise in drug combination
5. Weekly dose reduces targeted drugs side effects, but not its activity against ALL
6. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
7. Antiretroviral treatment for HIV reduces food insecurity, reports AIDS Journal
8. Alcohol provides protective effect, reduces mortality substantial
9. Innovative sobriety project reduces DUI and domestic violence arrests, study finds
10. National study shows protective eyewear reduces eye, head, and facial injuries
11. Soothing sounds during cataract surgery reduces patient anxiety
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: